TY - JOUR
T1 - Malignant carotid body tumors
T2 - What we know, what we do, and what we need to achieve. A systematic review of the literature
AU - Piazza, Cesare
AU - Lancini, Davide
AU - Tomasoni, Michele
AU - Zafereo, Mark
AU - Poorten, Vincent Vander
AU - Hanna, Ehab
AU - Mäkitie, Antti A.
AU - Fernandez-Alvarez, Veronica
AU - Kowalski, Luiz P.
AU - Chiesa-Estomba, Carlos
AU - Ferlito, Alfio
N1 - Publisher Copyright:
© 2024 The Authors. Head & Neck published by Wiley Periodicals LLC.
PY - 2024/3
Y1 - 2024/3
N2 - Malignant carotid body tumors (MCBT) are rare and diagnosed after detection of nodal or distant metastases. This systematic review (SR) focuses on MCBT initially approached by surgery. Preferred Reporting Items for SR and Meta-Analysis (MA) guided the articles search from 2000 to 2023 on PubMed, Scopus, and Web of Science. Among 3548 papers, 132 (337 patients) were considered for SR; of these, 20 (158 patients) for MA. Malignancy rate was 7.3%, succinate dehydrogenase (SDH) mutation 17%, age at diagnosis between 4th and 6th decades, with a higher prevalence of females. MCBTs were mostly Shamblin III, with nodal and distant metastasis in 79.7% and 44.7%, respectively. Malignancy should be suspected if CBT >4 cm, Shamblin III, painful or otherwise symptomatic, at the extremes of age, bilateral, with multifocal disease, and SDHx mutations. Levels II–III clearance should be performed to exclude nodal metastases and adjuvant treatments considered on a case-by-case basis.
AB - Malignant carotid body tumors (MCBT) are rare and diagnosed after detection of nodal or distant metastases. This systematic review (SR) focuses on MCBT initially approached by surgery. Preferred Reporting Items for SR and Meta-Analysis (MA) guided the articles search from 2000 to 2023 on PubMed, Scopus, and Web of Science. Among 3548 papers, 132 (337 patients) were considered for SR; of these, 20 (158 patients) for MA. Malignancy rate was 7.3%, succinate dehydrogenase (SDH) mutation 17%, age at diagnosis between 4th and 6th decades, with a higher prevalence of females. MCBTs were mostly Shamblin III, with nodal and distant metastasis in 79.7% and 44.7%, respectively. Malignancy should be suspected if CBT >4 cm, Shamblin III, painful or otherwise symptomatic, at the extremes of age, bilateral, with multifocal disease, and SDHx mutations. Levels II–III clearance should be performed to exclude nodal metastases and adjuvant treatments considered on a case-by-case basis.
KW - carotid body tumor
KW - malignant
KW - metastasis
KW - surgery
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85181523734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181523734&partnerID=8YFLogxK
U2 - 10.1002/hed.27624
DO - 10.1002/hed.27624
M3 - Review article
C2 - 38179805
AN - SCOPUS:85181523734
SN - 1043-3074
VL - 46
SP - 672
EP - 687
JO - Head and Neck
JF - Head and Neck
IS - 3
ER -